Torrent Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹3,303Cr
- +17.6% YoY
- 0% QoQ
- Net profit
- ₹635Cr
- +26.2% YoY
- +7.4% QoQ
- Margin
- 33%
- 0 pp YoY
- 0 pp QoQ
Guidance rank: #57 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.
From Torrent Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. (Page 4)
- Brazil branded generics market grew 10% YoY; Torrent grew 13% with healthy volume growth and mid-single digit pricing increase; expects 5-6 new product launches in Brazil. (Pages 3, 14)
- U.S. business saw 12% growth in constant currency; targeting a directional increase in sales with at least 5-7 launches per year and aims to cross $200 million annual sales by FY27. (Pages 3, 9)
- Germany facing supply disruptions, growth affected; alternative supplier efforts ongoing but will take 3-4 quarters. (Page 4)
2 more points from Torrent Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Torrent Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- There is mention of ongoing work to address supply disruptions in Germany by moving some products to Torrent's own facilities, which implies some capital investment in manufacturing (Page 4).
- Overall, the focus appears to be on integration with the JB acquisition, operational synergies, and expanding market presence rather than large announced capex at this stage.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Torrent Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Torrent Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit
Torrent Pharmaceuticals Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 3,303 | 2,809 | +17.6% | 3,302 | 0% |
| Operating profit (EBITDA) | 1,088 | 914 | +19% | 1,083 | +0.5% |
| Operating margin | 33% | 33% | 0 pp | 33% | 0 pp |
| Profit before tax | 814 | 691 | +17.8% | 791 | +2.9% |
| Net profit (PAT) | 635 | 503 | +26.2% | 591 | +7.4% |
| EPS (₹) | 18.76 | 14.86 | +26.2% | 17.46 | +7.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹5.0K Cr, net profit ₹534 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Torrent Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Torrent Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Torrent Pharmaceuticals Ltd Q3 FY26 results?
India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.
What is Torrent Pharmaceuticals Ltd share price analysis?
Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 82.4 with a market cap of ₹183,832 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
